UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Kinase drug discovery 20 years after imatinib: progress and future directions

Nature reviews. Drug discovery, 2021-07, Vol.20 (7), p.551-569

2021

Volltextzugriff (PDF)

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Nature medicine, 2015-06, Vol.21 (6), p.560-562

2015

Volltextzugriff (PDF)

The quest to overcome resistance to EGFR-targeted therapies in cancer

Nature medicine, 2013-11, Vol.19 (11), p.1389-1400

2013

Volltextzugriff (PDF)

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Clinical cancer research, 2008-05, Vol.14 (10), p.2895-2899

2008

Volltextzugriff (PDF)

Kinase drug discovery 20 years after imatinib

Nature reviews. Drug discovery, 2022-04

2022

Volltextzugriff (PDF)

New Targetable Oncogenes in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1097-1104

2013

Volltextzugriff (PDF)

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Science (American Association for the Advancement of Science), 2007-05, Vol.316 (5827), p.1039-1043

2007

Volltextzugriff (PDF)

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical cancer research, 2015-09, Vol.21 (17), p.3913-3923

2015

Volltextzugriff (PDF)

False positive plasma genotyping due to clonal hematopoiesis

Clinical cancer research, 2018-09, Vol.24 (18), p.4437-4443

2018

Volltextzugriff (PDF)

Overcoming therapy resistance in EGFR-mutant lung cancer

Nature cancer, 2021-04, Vol.2 (4), p.377-391

2021

Volltextzugriff (PDF)

The biology and treatment of EML4-ALK non-small cell lung cancer

European journal of cancer (1990), 2010-07, Vol.46 (10), p.1773-1780

2010

Volltextzugriff (PDF)

Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

Clinical cancer research, 2021-07, Vol.27 (13), p.3528-3539

2021

Volltextzugriff (PDF)

Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor

Angewandte Chemie (International ed.), 2014-01, Vol.53 (1), p.199-204

International ed. in English, 2014

Volltextzugriff (PDF)

Selumetinib plus docetaxel for KRAS -mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

The lancet oncology, 2013, Vol.14 (1), p.38-47

2013

Volltextzugriff (PDF)

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Cell, 2015-02, Vol.160 (5), p.977-989

2015

Volltextzugriff (PDF)

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

Journal of medicinal chemistry, 2018-05, Vol.61 (9), p.4249-4255

2018

Volltextzugriff (PDF)

Targeting MET Dysregulation in Cancer

Cancer discovery, 2020-07, Vol.10 (7), p.922-934

2020

Volltextzugriff (PDF)

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.841-849

2018

Volltextzugriff (PDF)

Basket trials and the evolution of clinical trial design in an era of genomic medicine

Journal of clinical oncology, 2015-03, Vol.33 (9), p.975-977

2015

Volltextzugriff (PDF)

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Nature (London), 2009-12, Vol.462 (7276), p.1070-1074

2009

Volltextzugriff (PDF)

Circumventing cancer drug resistance in the era of personalized medicine

Cancer discovery, 2012-03, Vol.2 (3), p.214-226

2012

Volltextzugriff (PDF)

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

Clinical cancer research, 2009-04, Vol.15 (8), p.2630-2636

2009

Volltextzugriff (PDF)

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Clinical cancer research, 2008-07, Vol.14 (13), p.4275-4283

2008

Volltextzugriff (PDF)

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Cancer research (Chicago, Ill.), 2007-12, Vol.67 (24), p.11924-11932

2007

Volltextzugriff (PDF)

Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies

Journal of clinical oncology, 2023-07, Vol.41 (21), p.3747-3761

2023

Volltextzugriff (PDF)

1 – 25 von 10.624

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(7.669)
Mit Volltextzugriff
(9.182)

Publikationsform

7 weitere anzeigen...

Weniger anzeigen...

Sprache

13 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(5.823)
Life Sciences & Biomedicine
(3.281)
Technology
(2.141)
Humans
(2.064)
Computer Science
(1.276)
Male
(1.202)
Female
(1.120)
Physical Sciences
(949)
Engineering
(863)
Biological And Medical Sciences
(804)
Middle Aged
(743)
Adult
(650)
Medical Sciences
(616)
Aged
(613)
Computer Science, Artificial Intelligence
(584)
Animals
(552)
Engineering, Electrical & Electronic
(509)
Exact Sciences And Technology
(496)
Computer Science, Information Systems
(486)
Computer Science, Theory & Methods
(479)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect
(4.201)
EZB Electronic Journals Library
(3.492)
MEDLINE
(2.622)
Journals@Ovid
(1.881)
IngentaConnect Journals
(1.602)
Access via ScienceDirect (Elsevier)
(1.497)
NUS Single-Journal Subscriptions
(1.220)
Ebook Central Perpetual and DDA
(1.133)
eBooks on EBSCOhost
(1.059)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.032)
Wiley Online Library Journals
(979)
IEEE Electronic Library Online
(907)
HEAL-Link subscriptions: Springer Book Series
(858)
Wiley Online Library
(674)
SpringerLink_现刊
(603)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(354)
Taylor & Francis Journals
(354)
Taylor & Francis Journals Complete
(345)
Taylor & Francis
(338)
Oxford Journals
(287)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(157)
Cancer Research
(125)
Clinical Cancer Research
(80)
Journal Of Thoracic Oncology
(67)
Monthly Notices Of The Royal Astronomical Society
(67)
Boreal Environment Research
(56)
Plos One
(56)
Stroke
(56)
Ieee Transactions On Antennas And Propagation
(53)
Blood
(52)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Kinase drug discovery 20 years after imatinib: progress and future directions

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

The quest to overcome resistance to EGFR-targeted therapies in cancer

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Kinase drug discovery 20 years after imatinib

New Targetable Oncogenes in Non–Small-Cell Lung Cancer

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

False positive plasma genotyping due to clonal hematopoiesis

Overcoming therapy resistance in EGFR-mutant lung cancer

The biology and treatment of EML4-ALK non-small cell lung cancer

Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor

Selumetinib plus docetaxel for KRAS -mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

Targeting MET Dysregulation in Cancer

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Basket trials and the evolution of clinical trial design in an era of genomic medicine

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Circumventing cancer drug resistance in the era of personalized medicine

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies

Suchergebnisse filtern